Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DANESH A ALAM

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1043227200
CMS profile
1133215
Location
WINFIELD, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,068.69

8 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $939.26 3
Food and Beverage $129.43 5

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Pharmaceuticals, Inc $1,049.86 7
Otsuka America Pharmaceutical, Inc. $18.83 1

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DANESH A ALAM

NPI 1043227200 · CMS profile ID 1133215

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

WINFIELD, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043227200?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DANESH A ALAM, NPI 1043227200, CMS profile ID 1133215. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043227200?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). DANESH A ALAM, NPI 1043227200, CMS profile ID 1133215. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043227200?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
DANESH A ALAM, NPI 1043227200, CMS profile ID 1133215, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1043227200?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

8 matching records · $1,068.69 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 8 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–8 of 8.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $15.7211/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078014616 CMS
Janssen Pharmaceuticals, Inc $47.4911/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078014620 CMS
Janssen Pharmaceuticals, Inc $15.7311/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078014624 CMS
Janssen Pharmaceuticals, Inc $31.6611/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078014632 CMS
Janssen Pharmaceuticals, Inc $277.8411/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078014606 CMS
Janssen Pharmaceuticals, Inc $164.3311/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078014610 CMS
Janssen Pharmaceuticals, Inc $497.0911/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078014638 CMS
Otsuka America Pharmaceutical, Inc. $18.8308/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118850406 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $17,495.83 24
PY2020 $2,250.00 4
PY2024 $1,068.69 8
PY2025 $16,767.00 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,292.36 12
PY2025 Principal investigator $131,175.91 17
PY2024 Principal investigator $333,688.72 94
PY2023 Principal investigator $642,167.72 100
PY2022 Principal investigator $346,465.71 57
PY2021 Principal investigator $149,586.53 50
PY2020 Principal investigator $478,016.95 67
PY2019 Recipient $1,282.88 8
PY2019 Principal investigator $534,507.18 49

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

57 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan Inc. $630.00 12/31/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, EFFICACY AND SAFETY STUDY OF RAPASTINEL FOR RAPID TREATMENT OF SYMPTOMS OF DEPRESSION AND SUICIDALITY IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670119725
Principal investigator 1 Allergan Inc. $3,396.04 12/31/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 670122109
Principal investigator 1 Allergan Inc. $10,457.96 12/31/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670123395
Principal investigator 1 Allergan Inc. $9,032.60 12/16/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 670112943
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $186.19 12/06/2019 Covered Recipient Physician A MULTICENTER, RANDOMIZED, FLEXIBLE-DOSE, DOUBLE BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE TREATMENT OF ADULTS WITH BORDERLINE PERSONALITY DISORDER No dispute reported 06/30/2026 696048869
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $126.79 12/06/2019 Covered Recipient Physician A MULTICENTER, RANDOMIZED, FLEXIBLE-DOSE, DOUBLE BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE TREATMENT OF ADULTS WITH BORDERLINE PERSONALITY DISORDER No dispute reported 06/30/2026 696048871
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $50.00 12/06/2019 Covered Recipient Physician A MULTICENTER, RANDOMIZED, FLEXIBLE-DOSE, DOUBLE BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE TREATMENT OF ADULTS WITH BORDERLINE PERSONALITY DISORDER No dispute reported 06/30/2026 696048873
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $50.00 12/06/2019 Covered Recipient Physician A MULTICENTER, RANDOMIZED, FLEXIBLE-DOSE, DOUBLE BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE TREATMENT OF ADULTS WITH BORDERLINE PERSONALITY DISORDER No dispute reported 06/30/2026 696048875
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $80.36 12/06/2019 Covered Recipient Physician A MULTICENTER, RANDOMIZED, FLEXIBLE-DOSE, DOUBLE BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE TREATMENT OF ADULTS WITH BORDERLINE PERSONALITY DISORDER No dispute reported 06/30/2026 696048877
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $537.75 12/05/2019 Covered Recipient Physician A MULTICENTER, RANDOMIZED, FLEXIBLE-DOSE, DOUBLE BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE TREATMENT OF ADULTS WITH BORDERLINE PERSONALITY DISORDER No dispute reported 06/30/2026 696048863
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $126.79 12/05/2019 Covered Recipient Physician A MULTICENTER, RANDOMIZED, FLEXIBLE-DOSE, DOUBLE BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE TREATMENT OF ADULTS WITH BORDERLINE PERSONALITY DISORDER No dispute reported 06/30/2026 696048865
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $125.00 12/05/2019 Covered Recipient Physician A MULTICENTER, RANDOMIZED, FLEXIBLE-DOSE, DOUBLE BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE TREATMENT OF ADULTS WITH BORDERLINE PERSONALITY DISORDER No dispute reported 06/30/2026 696048867
Principal investigator 1 Allergan Inc. $3,549.20 11/22/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670103369
Principal investigator 1 Allergan Inc. $14,000.00 11/20/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 670102987
Principal investigator 1 Genentech, Inc. $11,718.00 11/20/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
GANTENERUMAB IN EARLY AD No dispute reported 06/30/2026 681097445
Principal investigator 1 Allergan Inc. $4,872.55 11/13/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 670097223
Principal investigator 1 ACADIA Pharmaceuticals Inc $290.73 11/06/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
ACP-103-045 No dispute reported 06/30/2026 699990263
Principal investigator 1 Allergan Inc. $16,369.45 10/23/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670090315
Principal investigator 1 ACADIA Pharmaceuticals Inc $11,458.45 10/18/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
ACP-103-045 No dispute reported 06/30/2026 699990159
Principal investigator 1 Allergan Inc. $12,984.60 10/17/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 670087133
Principal investigator 1 Genentech, Inc. $4,897.00 10/02/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
GANTENERUMAB IN EARLY AD No dispute reported 06/30/2026 681101533
Principal investigator 1 Allergan Inc. $315.00 10/01/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, EFFICACY AND SAFETY STUDY OF RAPASTINEL FOR RAPID TREATMENT OF SYMPTOMS OF DEPRESSION AND SUICIDALITY IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670080965
Principal investigator 1 Allergan Inc. $169.00 10/01/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, EFFICACY AND SAFETY STUDY OF RAPASTINEL FOR RAPID TREATMENT OF SYMPTOMS OF DEPRESSION AND SUICIDALITY IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670080997
Principal investigator 1 Allergan Inc. $12,457.35 09/19/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 670078495
Principal investigator 1 Allergan Inc. $9,930.35 09/13/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670075345
Principal investigator 1 Genentech, Inc. $1,515.00 09/08/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
GANTENERUMAB IN EARLY AD No dispute reported 06/30/2026 681102463
Principal investigator 1 ACADIA Pharmaceuticals Inc $5,800.42 09/04/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
ACP-103-045 No dispute reported 06/30/2026 699989803
Principal investigator 1 Allergan Inc. $13,788.30 08/23/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670068919
Principal investigator 1 Janssen Research & Development, LLC $6,437.00 08/08/2019 Non-covered Recipient Entity
NEUROPSYCHIATRIC RESEARCH & PRACTIC E ASSOCIATES LTD
A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Subjects Assessed to be at Imminent Risk for Suicide No dispute reported 06/30/2026 654253713
Principal investigator 1 ACADIA Pharmaceuticals Inc $6,132.11 08/07/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
ACP-103-045 No dispute reported 06/30/2026 699989659
Principal investigator 1 Allergan Inc. $6,451.45 08/01/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC No dispute reported 06/30/2026 670062269
Principal investigator 1 Allergan Inc. $18,303.65 07/30/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670062045
Principal investigator 1 Allergan Inc. $24,649.65 07/09/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC No dispute reported 06/30/2026 670055291
Principal investigator 1 ACADIA Pharmaceuticals Inc $3,279.29 07/05/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
ACP-103-045 No dispute reported 06/30/2026 699989481
Principal investigator 1 Allergan Inc. $4,181.90 06/11/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC No dispute reported 06/30/2026 670050907
Principal investigator 1 ACADIA Pharmaceuticals Inc $2,131.11 06/06/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
ACP-103-045 No dispute reported 06/30/2026 699989327
Principal investigator 1 Genentech, Inc. $8,849.00 06/05/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
GANTENERUMAB IN EARLY AD No dispute reported 06/30/2026 681081397
Principal investigator 1 ACADIA Pharmaceuticals Inc $10,536.49 05/21/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
ACP-103-045 No dispute reported 06/30/2026 699989197
Principal investigator 1 ACADIA Pharmaceuticals Inc $5,082.00 05/21/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
ACP-103-045 No dispute reported 06/30/2026 699989199
Principal investigator 1 Allergan Inc. $1,300.00 05/21/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC No dispute reported 06/30/2026 670046882
Principal investigator 1 Allergan Inc. $6,000.00 05/21/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC No dispute reported 06/30/2026 670047075
Principal investigator 1 Allergan Inc. $3,297.00 05/21/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670047199
Principal investigator 1 Janssen Research & Development, LLC $10,235.00 05/16/2019 Non-covered Recipient Entity
NEUROPSYCHIATRIC RESEARCH & PRACTIC E ASSOCIATES LTD
A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Subjects Assessed to be at Imminent Risk for Suicide No dispute reported 06/30/2026 654253711
Principal investigator 1 Allergan Inc. $10,000.00 04/18/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients with Major Depressive Disorder No dispute reported 06/30/2026 670038861
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $88,070.35 04/15/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
AN OPEN-LABEL, 52-WEEK, MULTICENTER TRIAL EVALUATING THE LONG-TERM SAFETY AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER No dispute reported 06/30/2026 696054117
Principal investigator 1 ACADIA Pharmaceuticals Inc $416.75 04/05/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
ACP-103-045 No dispute reported 06/30/2026 699988855
Principal investigator 1 Allergan Inc. $10,000.00 04/02/2019 Non-covered Recipient Entity
NEUROPSYCHIATRIC RESEARCH AND PRACTICE ASSOCIATES
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, FIXED-DOSE CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY AND TOLERABILITY OF CARIPRAZINE IN PATIENTS WITH BIPOLAR I DEPRESSION No dispute reported 06/30/2026 670035643
Principal investigator 1 Janssen Research & Development, LLC $1,096.00 03/29/2019 Non-covered Recipient Entity
NEUROPSYCHIATRIC RESEARCH & PRACTIC E ASSOCIATES LTD
A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Subjects Assessed to be at Imminent Risk for Suicide No dispute reported 06/30/2026 654253709
Principal investigator 1 Allergan Inc. $2,701.80 03/12/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC No dispute reported 06/30/2026 670029971
Principal investigator 1 Janssen Research & Development, LLC $8,738.00 03/04/2019 Non-covered Recipient Entity
NEUROPSYCHIATRIC RESEARCH & PRACTIC E ASSOCIATES LTD
A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Subjects Assessed to be at Imminent Risk for Suicide No dispute reported 06/30/2026 654253705
Principal investigator 1 Allergan Inc. $2,226.00 01/29/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF VILAZODONE IN PEDIATRIC PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670019667
Principal investigator 1 Janssen Research & Development, LLC $7,715.00 01/28/2019 Non-covered Recipient Entity
NEUROPSYCHIATRIC RESEARCH & PRACTIC E ASSOCIATES LTD
A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Subjects Assessed to be at Imminent Risk for Suicide No dispute reported 06/30/2026 654253707
Principal investigator 1 ACADIA Pharmaceuticals Inc $8,000.00 01/23/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
ACP-103-045 No dispute reported 06/30/2026 699988225
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $9,311.85 01/19/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A MULTICENTER, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF BREXPIPRAZOLE IN THE TREATMENT OF SUBJECTS WITH BIPOLAR I DISORDER No dispute reported 06/30/2026 696053220
Principal investigator 1 Allergan Inc. $2,175.00 01/17/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A MULTICENTER, DOUBLE BLIND, PLACEBO AND ACTIVE-CONTROLLED PARALLEL-GROUP EVALUATION OF THE SAFETY AND EFFICACY OF VILAZODONE IN PEDIATRIC PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670017531
Principal investigator 1 Allergan Inc. $8,000.00 01/15/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC No dispute reported 06/30/2026 670016947
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $111,558.78 01/10/2019 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
PROTOCOL 331-201-00081 A MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE ACUTE TREATMENT OF MANIC EPISODES, WITH OR WITHOUT MIXED FEATURES, ASSOCIATED WITH BIPOLAR I DISORDER No dispute reported 06/30/2026 696052977